Propanc Biopharma, Inc. (PPCB): debt financing — Propanc Biopharma issues $67,860 convertible note with 35% conversion discount to 1800 Diagonal Lending

Propanc Biopharma, Inc.

Principal $67,860 for net $58,000; matures Apr 16, 2026; 15% one-time interest.
Conversion at 65% of lowest trading price in prior 10 days (35% discount); dilution risk.
Payments: $39,019.50 on Dec 15, 2025; then $9,754.88 on Jan 15, Feb 15, Mar 15, Apr 15, 2026.
Default triggers immediate acceleration; includes failure to pay, maintain OTC listing, or SEC reporting.
Proceeds for general working capital; note issued under Regulation D, not registered.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Propanc Biopharma, Inc. incurred convertible notes of $67,860.00 with an investor at one-time interest charge of fifteen percent (15%) maturing April 16, 2026.

Instrument: convertible notes
Principal: $67,860.00
Counterparty: an investor
Rate: one-time interest charge of fifteen percent (15%)
Maturity: April 16, 2026
Event: incurrence

Exact text from the filing

with an investor (the “Investor”) pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $67,860.00 (the “Note”), for a purchase price of $58,000. The Company intends to use the net proceeds therefrom for general working capital purposes. The maturity date of the Note is April

View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

Propanc Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-016719

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.